rev:       April 28, 2004

HOME (index page)

Return (alphabetical antibody page)

Return  (cytokeratin data page)


CYTOKERATIN   ANTIBODIES  

(anti-Human and others as indicated)

RDI Divison of Fitzgerald Industries Intl  offers a wide line of  antibodies. Since no one antibody works best for all applications (neutralization, blotting, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.


ANTI-CYTOKERATIN 6


Mab to Cytokeratin 6

cat#RDI-PRO65190     $344.00/vial 5ml


Clone                                       Ks6.KA12

Category                                 Mouse monoclonal

Ig Subclass                              IgG1

Purification/Form                     Hybridoma culture supernatant (contains 0.1% sodium azide)

Antigen                                   Cytokeratin 6 of human callus cytoskeletal preparation


Clinical Application/  

Specificity                                Ks6.KA12 represents an excellent marker for non-keratinized squamous epithelia and                                                         proliferating cells of epidermis (e.g. within psoriatic lesions).

Application Suitable for· immunohistochemistry on frozen tissue and paraffin-embedded material (P) after formalin- fixation; microwave treatment improves performance· immunoblotting (Western blot)

Storage/Stability at 4°C (undiluted) for min 1 year

Volume 5 ml

Polypeptide Reacting Mr 56 000 polypeptide (cytokeratin 6) of human squamous epithelia

Antigen Recognized in Species (tested so far)  Human , mouse (see below cat#RDI-PRO61090)

Reactivities Cell Lines (tested so far) :    Cultured A-431, Detroit 562, SCC-12

Tissues and Tumors Specifically Detectedor: The antibody is suitable for discrimination of keratinizing and non-keratinizing squamous cell carcinoma versus e.g. poorly differentiated adenocarcinoma.

Working Dilution Ready-to-use for immunohistochemistry

Incubation Time 1 h at RT, extended with (P) for immu-nohistochemical application



References

Smedts F et al. Keratin expression in cervical cancer. Am J Pathol 141:497-511 (1992)

Wetzels RHW et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 138:751-763 (1991)

Demirkesen C, Hoede N, Moll R: Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeratins. J Cutan Pathol 22: 518-535 (1995).

Moll R. et al.: Differenzierungsmarker bei gynäkologischen Tumoren: Methodische und diagnostische Aspekte. In: Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie. W. Zuckschwerdt Verlag (1995).
For research use only. Not supplied for use in human diagnostic or therapeutic procedures


Mab to Cytokeratin 6

cat#RDI-PRO61090  $406.00/vial 50ug

   (same clone as cat#RDI-PRO65190 , now purified)

Clone Ks6                .KA12

Category                   Mouse monoclonal

Ig Subclass                IgG1

Purification/Form      A affinity chromatography

Antigen                      Cytokeratin 6 of human callus cytoskeletal preparation

Clinical Application/Specificity:  Ks6.KA12 represents an excellent marker for non-.

                                keratinized squamous epithelia and proliferating cells of epidermis (e.g. within psoriatic lesions).

Application   Suitable for

   · immunohistochemistry on frozen tissue and paraffin-embedded material (P) after formalin- fixation; microwave treatment improves performance· immunoblotting (Western blot)

Storage/Stability                     at 2-8°C (undiluted) for min 1 year

Volume                                   50 micrograms lyophilized (contain 0.5% BSA and 0.09% NaN3)

Polypeptide Reacting              Mr 56 000 polypeptide (cytokeratin 6) of human squamous epithelia

Antigen Recognized in Species (tested so far) Human  mouse+

Reactivities on Cultured            A-431, Detroit 562, SCC-12

Cell Lines (tested so far)

Tissues and Tumors  specifically detected:

          The antibody is suitable for discrimina  of keratinizing and non-keratinizing squamous cell carcinoma versus e.g. poorly differentiated adenocarcinoma.

Working Dilution econstitute with 1ml DI water, use approx 1:10 dilution with PBS for immunohisto-chemistry

Incubation Time 1 h at RT, extended with (P) for immuno-histochemical application

References

Smedts F et al. Keratin expression in cervical cancer. Am J Pathol 141:497-511 (1992)

Wetzels RHW et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 138:751-763 (1991)

Demirkesen C, Hoede N, Moll R: Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeratins. J Cutan Pathol 22: 518-535 (1995).

Moll R. et al.: Differenzierungsmarker bei gynäkologischen Tumoren: Methodische und diagnostische Aspekte. In: Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie. W. Zuckschwerdt Verlag (1995).

+ Herrman T et al , Mice with targeted disruption of the fatty acid transport protein 4 (FATp 4, SIc27a4) gene show features of lethal restrictive dermopathy. J Cell Biol 161, 1105-1115 (2003)

For In Vitro Research Use Only


RDI Divison of Fitzgerald Industries Intl

34 Junction Square Drive

Concord MA 01742-3049

USA

phone (978) 371-6446 or (800) 370-2222

fax     (978) 371-2266

EMAIL:antibodies@fitzgerald-fii.com

Ordering terms

RETURN(cytokeratin page)

Return (alphabetical antibody page)